Symptoms of overdose may include excessive bleeding and bruising.
Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500. Normiflo was withdrawn from the US market in March 2000.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | Apixaban may increase the anticoagulant activities of Ardeparin. |
| Dabigatran etexilate | Dabigatran etexilate may increase the anticoagulant activities of Ardeparin. |
| Dasatinib | The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Ardeparin. |
| Deferasirox | The risk or severity of gastrointestinal bleeding can be increased when Ardeparin is combined with Deferasirox. |
| Ursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Ardeparin is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Ardeparin is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of bleeding and bruising can be increased when Ardeparin is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of bleeding and bruising can be increased when Ardeparin is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of bleeding and bruising can be increased when Ardeparin is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of bleeding and bruising can be increased when Ardeparin is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of bleeding and bruising can be increased when Ardeparin is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Ardeparin is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Ardeparin is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Ardeparin is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of bleeding and bruising can be increased when Ardeparin is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of bleeding and bruising can be increased when Ardeparin is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Ardeparin is combined with Hyodeoxycholic Acid. |
| Edoxaban | The risk or severity of bleeding can be increased when Edoxaban is combined with Ardeparin. |
| Ibrutinib | The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Ardeparin. |
| Obinutuzumab | The risk or severity of bleeding and hemorrhage can be increased when Ardeparin is combined with Obinutuzumab. |
| Rivaroxaban | Ardeparin may increase the anticoagulant activities of Rivaroxaban. |
| Sugammadex | The risk or severity of bleeding and hemorrhage can be increased when Ardeparin is combined with Sugammadex. |
| Tibolone | Tibolone may increase the anticoagulant activities of Ardeparin. |
| Tipranavir | The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Ardeparin. |
| Urokinase | Urokinase may increase the anticoagulant activities of Ardeparin. |
| Vitamin E | Vitamin E may increase the anticoagulant activities of Ardeparin. |
| Vorapaxar | The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Ardeparin. |
| Trandolaprilat | The risk or severity of hyperkalemia can be increased when Trandolaprilat is combined with Ardeparin. |
| Moexiprilat | The risk or severity of hyperkalemia can be increased when Moexiprilat is combined with Ardeparin. |
| Cilazaprilat | The risk or severity of hyperkalemia can be increased when Cilazaprilat is combined with Ardeparin. |
| Ginkgo biloba | Ginkgo biloba may increase the anticoagulant activities of Ardeparin. |
| Ifosfamide | The risk or severity of bleeding can be increased when Ifosfamide is combined with Ardeparin. |
| Quinine | The therapeutic efficacy of Ardeparin can be increased when used in combination with Quinine. |
| Quinidine | The therapeutic efficacy of Ardeparin can be increased when used in combination with Quinidine. |
| Tamoxifen | The risk or severity of bleeding can be increased when Tamoxifen is combined with Ardeparin. |
| Toremifene | The risk or severity of bleeding can be increased when Toremifene is combined with Ardeparin. |
| Corticorelin ovine triflutate | The risk or severity of hypotension and sinus node depression can be increased when Ardeparin is combined with Corticorelin ovine triflutate. |
| Oritavancin | The therapeutic efficacy of Ardeparin can be decreased when used in combination with Oritavancin. |
| Streptokinase | Streptokinase may increase the anticoagulant activities of Ardeparin. |
| Telavancin | The therapeutic efficacy of Ardeparin can be decreased when used in combination with Telavancin. |
| Palifermin | The serum concentration of Palifermin can be increased when it is combined with Ardeparin. |
| Pentoxifylline | The therapeutic efficacy of Ardeparin can be increased when used in combination with Pentoxifylline. |
| Pentosan polysulfate | Pentosan polysulfate may increase the anticoagulant activities of Ardeparin. |
| Levocarnitine | The therapeutic efficacy of Ardeparin can be increased when used in combination with Levocarnitine. |
| Diethylstilbestrol | Diethylstilbestrol may decrease the anticoagulant activities of Ardeparin. |
| Chlorotrianisene | Chlorotrianisene may decrease the anticoagulant activities of Ardeparin. |
| Conjugated estrogens | Conjugated estrogens may decrease the anticoagulant activities of Ardeparin. |
| Mestranol | The risk or severity of adverse effects can be increased when Mestranol is combined with Ardeparin. |
| Estrone sulfate | Estrone sulfate may decrease the anticoagulant activities of Ardeparin. |
| Quinestrol | Quinestrol may decrease the anticoagulant activities of Ardeparin. |
| Hexestrol | Hexestrol may decrease the anticoagulant activities of Ardeparin. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Ardeparin. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Ardeparin. |
| Polyestradiol phosphate | Polyestradiol phosphate may decrease the anticoagulant activities of Ardeparin. |
| Esterified estrogens | Esterified estrogens may decrease the anticoagulant activities of Ardeparin. |
| Zeranol | Zeranol may decrease the anticoagulant activities of Ardeparin. |
| Equol | Equol may decrease the anticoagulant activities of Ardeparin. |
| Methallenestril | Methallenestril may decrease the anticoagulant activities of Ardeparin. |
| Epimestrol | Epimestrol may decrease the anticoagulant activities of Ardeparin. |
| Moxestrol | Moxestrol may decrease the anticoagulant activities of Ardeparin. |
| Estradiol acetate | Estradiol acetate may decrease the anticoagulant activities of Ardeparin. |
| Estradiol benzoate | Estradiol benzoate may decrease the anticoagulant activities of Ardeparin. |
| Estradiol cypionate | Estradiol cypionate may decrease the anticoagulant activities of Ardeparin. |
| Estradiol valerate | Estradiol valerate may decrease the anticoagulant activities of Ardeparin. |
| Biochanin A | Biochanin A may decrease the anticoagulant activities of Ardeparin. |
| Formononetin | Formononetin may decrease the anticoagulant activities of Ardeparin. |
| Estriol | Estriol may decrease the anticoagulant activities of Ardeparin. |
| Limaprost | The risk or severity of adverse effects can be increased when Limaprost is combined with Ardeparin. |
| Icosapent | The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Ardeparin. |
| Mesalazine | The risk or severity of bleeding can be increased when Mesalazine is combined with Ardeparin. |
| Indomethacin | The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Ardeparin. |
| Nabumetone | The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Ardeparin. |
| Ketorolac | The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Ardeparin. |
| Tenoxicam | The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Ardeparin. |
| Celecoxib | The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Ardeparin. |
| Tolmetin | The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Ardeparin. |
| Rofecoxib | The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Ardeparin. |
| Piroxicam | The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Ardeparin. |
| Fenoprofen | The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Ardeparin. |
| Valdecoxib | The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Ardeparin. |
| Diclofenac | The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Ardeparin. |
| Sulindac | The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Ardeparin. |
| Flurbiprofen | The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Ardeparin. |
| Etodolac | The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Ardeparin. |
| Mefenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Ardeparin. |
| Naproxen | The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Ardeparin. |
| Sulfasalazine | The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Ardeparin. |
| Phenylbutazone | The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Ardeparin. |
| Meloxicam | The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Ardeparin. |
| Carprofen | The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Ardeparin. |
| Diflunisal | The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Ardeparin. |
| Salicylic acid | The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Ardeparin. |
| Meclofenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Ardeparin. |
| Oxaprozin | The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Ardeparin. |
| Ketoprofen | The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Ardeparin. |
| Balsalazide | The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Ardeparin. |
| Olsalazine | The risk or severity of bleeding can be increased when Ardeparin is combined with Olsalazine. |
| Lumiracoxib | The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Ardeparin. |
| Magnesium salicylate | The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Ardeparin. |
| Salsalate | The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Ardeparin. |